Feasbility and pharmacokinetics of carbamazepine oral loading doses

American Journal of Health-System Pharmacy

Volumn 55, Issue 11, 1998, Pages 1134-1140

  Cohen, Henry ^a,b   Howland, Mary Ann ^c,d   Luciano, Daniel J ^e   Rubin, Rochelle N ^f,g   Kutt, Henn ^h   Hoffman, Robert S ^i,j   Leung, Lucas K H ^k   Devinsky, Orrin ^g   Goldfrank, Lewis R ^l,m,n  

^a LONG ISLAND UNIVERSITY   (United States)

^b KINGSBROOK JEWISH MEDICAL CENTER   (United States)

^c ST JOHN'S UNIVERSITY   (United States)

^d NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^e NYU HOSPITAL FOR JOINT DISEASES   (United States)

^f SUNY DOWNSTATE MEDICAL CENTER   (United States)

^g HJD/OI ^*

^h WEILL CORNELL MEDICAL COLLEGE   (United States)

ⁱ NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j NYCPCC   (United States)

^k WEILL CORNELL MEDICAL CENTER   (United States)

^l NYUMC

^m School of Medicine

ⁿ NYCPCC ^*

more..

Author keywords

Anticonvulsants; Blood levels; Carbamazepine; Carbamazepine 10,11 epoxide; Dosage; Dosage schedules; Equivalency; Excretion; Half life; Metabolism; Pharmacokinetics; Suspensions; Tablets; Toxicity

Indexed keywords

CARBAMAZEPINE; CARBAMAZEPINE 10,11 OXIDE; DRUG METABOLITE; ANTICONVULSIVE AGENT;

ADULT; ANTICONVULSANT THERAPY; ARTICLE; BIOEQUIVALENCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM; DRUG HALF LIFE; DRUG METABOLISM; FEMALE; HEADACHE; HUMAN; MALE; NYSTAGMUS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEIZURE; SUSPENSION; TABLET; AREA UNDER THE CURVE; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; EPILEPSY; HALF LIFE TIME; METABOLIC CLEARANCE RATE; METABOLISM; MIDDLE AGED;

ADULT; ANTICONVULSANTS; AREA UNDER CURVE; CARBAMAZEPINE; EPILEPSY; FEMALE; HALF-LIFE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NYSTAGMUS, PATHOLOGIC;

EID: 0032081296     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/55.11.1134     Document Type: Article

References (33)

1. Ramsey EG, Wilder BJ, Berger JR et al. A double-blind study comparing carbamazepine with phenytoin as initial seizure therapy in adults. Neurology. 1983; 33:904-10.
2. Physicians' desk reference. 52nd ed. Oradell, NJ: Medical Economics; 1998:1905-8.
3. Porter RJ. How to initiate and maintain carbamazepine therapy in children and adults. Epilepsia. 1987; 28(suppl 3):S59-63.
4. Kiluk KI, Knighton RS, Newman JD. The treatment of trigeminal neuralgia and other facial pain with carbamazepine. Mich Med. 1968; 67:1066-9.
5. Blom S. Tic douloureux treated with new anticonvulsant experiences with G32883. Arch Neurol. 1963; 9:285-90.
6. Gamstorp I. Treatment with carbamazepine: children. Adv Neurol. 1975; 11:237-48.
7. Cereghino JJ, Brock JT, VanMeter JC et al. Carbamazepine for epilepsy: a controlled prospective evaluation. Neurology. 1974; 24:401-11.
8. Bass J, Miles MV, Tennison MB et al. Effects of enteral tube feeding on the absorption and pharmacokinetic profile of carbamazepine suspension. Epilepsia. 1989; 30:364-9.
9. Miles MV, Lawless ST, Tennison MB et al. Rapid loading of critically ill patients with carbamazepine suspension. Pediatrics. 1990; 86:263-6.
10. Leppik IE, Pascual-Leone A, Dhura A. Oral loading with carbamazepine: a pilot study. Epilepsia. 1988; 29:699-700. Abstract.
11. Kanner AM, Hudson P, Hasegawa H et al. A practical use of single-dose pharmacokinetic studies of carbamazepine. Epilepsia. 1990; 31:602. Abstract.
12. Tomson T, Almkvist O, Nilsson BY. Carbamazepine-10,11-epoxide in epilepsy: a pilot study. Arch Neurol. 1990; 47:888-92.
13. Levy RH, Bradley MK. Clinical pharmacokinetics of carbamazepine. J Clin Psychiatry. 1988; 49(suppl 4):58-61.
14. Kutt H, Solomon GE, Dhar AK et al. Effects of progabide on carbamazepine epoxide and carbamazepine concentrations in plasma. Epilepsia. 1984; 25:674. Abstract.
15. Meijer JWA, Binnie CD, Debets RMC et al. Possible hazard of valpromide-carbamazepine combination therapy in epilepsy. Lancet. 1984; 1:802. Letter.
16. Schoeman JF, Elyas AA, Brett EM et al. Correlation between plasma carbamazepine-10,11-epoxide concentration and drug side-effects in children with epilepsy. Dev Med Child Neurol. 1984; 26:756-64.
17. Rosenfeld WE, Holmes GB, Graves NM. Carbamazepine 10-11 epoxide serum concentrations as a predictor of toxicity. Epilepsia. 1987; 28:580-1. Abstract.
18. Tomson T, Bertilsson L. Potent therapeutic effect of carbamazepine-10,11-epoxide in trigeminal neuralgia. Arch Neurol. 1984; 41:598-601.
19. DiSalle E, Pacifici GM, Morselli PL. Studies on plasma protein binding of carbamazepine. Pharmacol Res Commun. 1974; 6:193-202.
20. Hooper WD, Dubetz F, Bochner F et al. Plasma protein binding of carbamazepine. Clin Pharmacol Ther. 1975; 18:433-10.
21. Morselli PL, Gevra M, DeMaro D et al. Pharmacokinetic studies of carbamazepine in volunteers and epileptic patients. In: Schneider H, ed. Clinical pharmacology of antiepileptic drugs. Berlin: Springer; 1975:166-82.
22. Bertilsson L. Clinical pharmacokinetics of carbamazepine. Clin Pharmacol. 1978; 3:128-43.
23. MacKichan JJ, Duffner PK, Cohen ME. Salivary concentrations and plasma protein binding of carbamazepine and carbamazepine-10,11-epoxide in epileptic patients. Br J Clin Pharmacol. 1981; 12:31-7.
24. Lawless LM, Demonaco HJ, Muido LR. Protein binding of carbamazepine in epileptic patients. Neurology. 1982; 32:415-8.
25. Riva R, Contin M, Albani F et al. Free and total plasma concentrations of carbamazepine and carbamazepine-10,11-epoxide in epileptic patients: diurnal fluctuations and relationship with side effects. Ther Drug Monit 1984; 6:408-13.
26. Riva R, Albani F, Ambrosetto G et al. Diurnal fluctuations in free and total steady-state plasma levels of carbamazepine and correlation with intermittent side effects. Epilepsia. 1984; 24:476-81.
27. Contin M, Riva R, Albani F et al. Alpha-1-acid glycoprotein concentration and serum protein binding of carbamazepine and carbamazepine-10,11-epoxide in children with epilepsy. Eur J Clin Pharmacol. 1985; 29:211-4.
28. Elyas AA, Patsalos PN, Agbato OA. Factors influencing simultaneous concentrations of total and free carbamazepine and carbamazepine-10,11-epoxide in serum of children with epilepsy. Ther Drug Monit. 1986; 8:288-92.
29. Wang R-B, Lin L-T, Yin C-H. Carbamazepine drug interactions: the influence of concurrent drug therapy on serum concentrations of carbamazepine and its epoxide metabolite. Chin Med J (Taipei). 1990; 45:222-32.
30. Dossing M. Time course of phenobarbital and cimetidine mediated changes in hepatic drug metabolism. Eur J Clin Pharmacol. 1983; 25:215-21.
31. Kutt H. Carbamazepine: chemistry and methods of determination. In: Levy R, Mattson R, Meldrum B et al., eds. Antiepileptic drugs. New York: Raven; 1989:465-6.
32. Brodie MJ, Forrest G, Rapeport WG. Carbamazepine 10,11-epoxide concentrations in epileptics on carbamazepine alone and in combination with other anticonvulsants. Br J Clin Pharmacol. 1983; 16:747-50.
33. Osborn HH, Zisfein J, Sparano R. Single-dose oral phenytoin loading. Ann Emerg Med. 1987; 16:407-12.